MARKSANS PHARMA
|
The Current P/E Ratio of MARKSANS PHARMA is 27.31.
| Share Price | ₹314.2 | Oct 14,2026 |
| Market Cap | ₹14,237.3 Cr | |
| Earnings-TTM | ₹521.3 Cr | TTM-Consolidated Results |
| Price/Earnings | 27.31x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of MARKSANS PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹14,237.3 Cr] as on Oct 14,2026
(/) Earnings [ ₹521.3 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 27.31x ]
Thus, for MARKSANS PHARMA , the investors are currently willing to pay 27.31 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of MARKSANS PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of MARKSANS PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of MARKSANS PHARMA
PE Ratio Performance Analysis for MARKSANS PHARMA
- MARKSANS PHARMA 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 17.50x.
- MARKSANS PHARMA 's operated at median p/e ratio of 17.04x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, MARKSANS PHARMA 's p/e ratio peaked in Mar2025 at 26.48x.
- MARKSANS PHARMA 's p/e ratio hit its five-year low in Mar2022 of 10.1x.
How does MARKSANS PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| MARKSANS PHARMA | 521.27 | 27.31 | 14,237.3 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 34.47 | 419,620.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 81.95 | 239,714.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 81.05 | 174,741.0 |
| CIPLA LTD | 3,364.84 | 31.52 | 106,061.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 31.98 | 101,339.0 |
| MANKIND PHARMA LTD | 2,055.11 | 46.83 | 96,243.6 |
| LUPIN LTD | 5,551.01 | 16.10 | 89,391.0 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 24.96 | 112,119.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 25.75 | 95,590.4 |
| LAURUS LABS LTD | 1,090.76 | 100.85 | 110,008.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs MARKSANS PHARMA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 16.10x |
| Max industry PE | 100.85x |
| Median industry PE | 31.98x |
| Average industry PE | 45.71x |
You may also like the below Video Courses